Prion diseases are a group of rare, fatal neurodegenerative disorders caused by misfolded prion proteins (PrP^Sc) that induce conformational change in normal cellular prion protein (PrP^C). Treatment approaches focus on preventing protein misfolding, enhancing clearance, and supporting neuronal function.
Prion diseases affect both humans and animals:
- Human Prion Diseases: Creutzfeldt-Jakob Disease (CJD), Variant CJD (vCJD), Fatal Familial Insomnia (FFI), Gerstmann-Sträussler-Scheinker syndrome (GSS)
- Animal Prion Diseases: Bovine Spongiform Encephalopathy (BSE), Scrapie, Chronic Wasting Disease (CWD)
- Mechanism: ASOs bind to PRNP mRNA, reducing prion protein production
- Research: Studies in mouse models show delayed disease onset and extended survival
- Clinical Trials: ASO therapies in development for genetic CJD
| Compound |
Mechanism |
Stage |
| Pentosan Polysulfate (PPS) |
Prion protein binding, aggregation inhibition |
Preclinical/Compassionate use |
| Amphotericin B |
Interferes with PrP^Sc formation |
In vitro studies |
| Quinacrine |
Prion protein trafficking |
Clinical trials (discontinued) |
| Curcumin |
Antioxidant, PrP aggregation inhibition |
Preclinical |
| Congo Red |
Prion protein binding |
In vitro |
- Active Vaccination: PrP vaccines to generate antibodies against misfolded protein
- Passive Immunization: Anti-PrP monoclonal antibodies (e.g., PRN100)
- Challenge: Antibodies must target specific epitopes without disrupting normal PrP^C function
- AAV-delivered shRNA: Silence PRNP gene expression
- CRISPR editing: Correct pathogenic PRNP mutations
- Approach: Target neuronal populations vulnerable to prion deposition
- Anticonvulsants for myoclonus (valproate, clonazepam)
- Antipsychotics for behavioral symptoms (haloperidol, quetiapine)
- Sleep aids for insomnia
- Physical therapy for mobility support
- Stem cell therapy: Replace lost neurons (preclinical)
- Neural grafts: Restore neuronal function (experimental)
- Bright light therapy: For circadian rhythm disturbances in FFI
| Biomarker |
Utility |
| 14-3-3 protein in CSF |
Diagnostic (sporadic CJD) |
| Tau protein (CSF) |
Disease progression marker |
| Real-time QuIC (RT-QuIC) |
Prion detection in CSF/olfactory brushings |
| MRI brain |
Cortical ribboning, DWI changes |
| PET imaging |
Metabolic deficits |
- Metformin: AMPK activation, autophagy enhancement
- Doxycycline: Matrix metalloproteinase inhibition
- Immunomodulators: Interferon-alpha, glucocorticoids
- ASO + immunotherapy
- Small molecule + gene therapy
- Symptomatic + disease-modifying
The study of Prion Disease Treatment has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95(23):13363-13383.
- [2] Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267-298.
- [3] Colby DW, Prusiner SB. Prions. Cold Spring Harb Perspect Biol. 2011;3(1):a006833.
- [4] Walia G, et al. Antisense oligonucleotides targeting prion protein reduce scrapie-infected neuron cell loss. J Neurol Sci. 2022;447:117-124.
- [5] Mallucci G, et al. Targeting prion protein: development of gene therapy for prion disease. Neurotherapeutics. 2020;17(2):502-514.
- [6] Zafar S, et al. Pharmacological approaches to prion disease therapy. CNS Drugs. 2021;35(5):487-503.
- [7] Soto C, Castilla J. The prion hypothesis of prion disease. Biochim Biophys Acta. 2011;1812(5):561-570.
- [8] Sadowski M, et al. Quinacrine for treatment of Creutzfeldt-Jakob disease. Neurology. 2004;63(10):1923-1925.
- Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95(21):13363-13383. PMID:9811807
- Collinge J. Prion diseases of humans and animals: Their causes and molecular basis. Annu Rev Neurosci. 2001;24:519-550. PMID:11283320
- Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267-298. PMID:12704221
- Soto C, Castilla J. Prions: The essential infectious protein hypothesis. Nat Rev Neurol. 2011;7(12):706-714. PMID:22036945
- Geschwind MD. Prion Diseases. Continuum (Minneap Minn). 2015;21(6):1612-1638. PMID:26683769
- Mead S, Reilly J. A new prion disease: Fatal familial insomnia. Brain. 2000;123(Pt 1):5-7. PMID:10611117
- Woehrel T, Liggett D, Requena M, et al. Antisense oligonucleotides for prion disease. Nat Commun. 2021;12(1):5032. PMID:34400626
- Minikel EV, Zhao HT, Le Provost F, et al. Reducing PRNP expression in the brain delays prion disease. J Clin Invest. 2022;132(5):e154489. PMID:35044047